The prostate health index (PHI) is a blood test that more accurately assesses the risk of prostate cancer than a traditional PSA test. The PHI combines three different PSA tests to create one risk ...

A multicomponent blood-based biomarker test that combines prostate-specific antigen (PSA) with additional plasma protein biomarkers, a polygenic risk score, and clinical variables identified more ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

The ArteraAI Prostate Test uses AI to analyze biopsy images, predicting hormone therapy benefits for prostate cancer patients. Approved in the US and UK, the test aids early diagnostic decisions, ...

A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...